Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare ALOGLIPTIN (Alogliptin) and Sitagliptin (Januvia) — clinical data, side effects, and patient experiences.
Alogliptin, Nesina, OSENI · DPP-4 Inhibitor
How it works
12.1 Mechanism of Action Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are releas...
Approved for
Januvia, ZITUVIMET · DPP-4 Inhibitor
How it works
Inhibits dipeptidyl peptidase-4 (DPP-4) enzyme, slowing the inactivation of incretin hormones GLP-1 and GIP, thereby increasing insulin release and decreasing glucagon levels in a ...
Approved for
Estimated frequency (%) based on clinical trial data
Based on 30 Reddit discussions
ALOGLIPTIN
0%
positive
15 threads
Sitagliptin
40%
positive
15 threads
% of discussions mentioning each side effect
Based on 1 verified patient review
No data yet
No data yet
Avg. Duration
0 months
0% still taking
Avg. Duration
18 months
100% still taking
Both ALOGLIPTIN and Sitagliptin belong to the DPP-4 Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.
Sitagliptin has an average efficacy rating of 7.0/10 and tolerability of 9.0/10 across 1 patient review. Patient-reported outcomes provide real-world context beyond clinical trials, though individual responses to medication vary significantly..
ALOGLIPTIN carries 4 FDA warnings. Sitagliptin carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.